(TheNewswire)
Ashkelon, Israel and Vancouver, BC - TheNewswire - January 23, 2023 - BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN ) (CSE: BYND ) (" BYNDCannasoft " or the " Company ") announced today that it signed an agreement forInvestor Relations and Public Relations Services to be provided byTriple Crown LLC, the Agreement includes services such as: CapitalStructure, Media Relations and Campaigns, M&A opportunities,financing opportunities, capital raising and public relations andinvestor relation functions which may include road shows, pressinterviews and other for the period from October 1, 2022 to December31, 2023. The Total Consideration for the above services for the 15months’ period is US $700,000.
About BYND Cannasoft Enterprises Inc.
BYND Cannasoft Enterprises is an Israeli-based integrated software andcannabis company. BYND Cannasoft owns and markets "BenefitCRM," a proprietary customer relationship management (CRM)software product enabling small and medium?sized businesses tooptimize their day?to?day business activities such as salesmanagement, personnel management, marketing, call center activities,and asset management. Building on our 20 years of experience in CRMsoftware, BYND Cannasoft is developing an innovative new CRM platformto serve the needs of the medical cannabis industry by making it amore organized, accessible, and price-transparent market. The CannabisCRM System will include a Job Management (BENEFIT) and a module system(CANNASOFT) for managing farms and greenhouses with varied crops. BYNDCannasoft owns the patent-pending intellectual property for the EZ-Gdevice. This therapeutic device uses proprietary software to regulatethe flow of low concentrations of CBD oil, hemp seed oil, and othernatural oils into the soft tissues of the female reproductive systemto potentially treat a wide variety of women's health issues. TheEZ-G device includes technological advancements as a sex toy with amore realistic experience and the prototype utilizes sensors todetermine what enhances the users' pleasure. The user can control thedevice through a Bluetooth app installed on a smartphone or otherportable device. The data will be transmitted and received from thedevice to and from the secure cloud using artificial intelligence(AI). The data is combined with other antonymic user preferences toimprove its operation by increasing sexual satisfaction.
For Further Information please refer to information available on the Company’swebsite: www.cannasoft-crm.com , theCSE’s website: www.thecse.com/en/listings/life-sciences/bynd-cannasoft-enterprises-inc and on SEDAR: www.sedar.com .
Gabi Kabazo
Chief Financial Officer
Tel: (604) 833-6820
e?mail: ir@cannasoft-crm.com
For Media and Investor Relations, pleasecontact:
David L. Kugelman
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Skype: kugsusa
Cautionary Note RegardingForward-Looking Statements
This press release contains forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of1995 involving risks and uncertainties, which may cause results todiffer materially from the statements made. We intend suchforward-looking statements to be covered by the safe harbor provisionsfor forward-looking statements contained in Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the SecuritiesExchange Act of 1934, as amended. When used in this document, thewords "may," "would," "could,""will," "intend," "plan,""anticipate," "believe," "estimate,""expect," "potential," "continue,""strategy," "future," "project,""target," and similar expressions are intended to identifyforward-looking statements, though not all forward lookingstatements use these words or expressions. All statements contained inthis press release other than statements of historical fact,including, without limitation, statements regarding changes to ourleadership team, our Cannabis CRM platform, our expanded EZ-G patentapplication, the expected benefits of our double-faceted condom designto users, our market growth, and our objectives for future operations,are forward looking statements. Additional regulatory standards maybe required, including FDA approval or any other approval for thepurpose of manufacturing, marketing, and selling the device undertherapeutic indications. There is no certainty that the aforementionedapprovals will be received, and all the information in this release isforward-looking. Such statements reflect the company's current viewswith respect to future events and are subject to such risks anduncertainties. Many factors could cause actual results to differmaterially from the statements made, including unanticipatedregulatory requests and delays, final patents approval, and thosefactors discussed in filings made by the company with the Canadiansecurities regulatory authorities, including (without limitation) inthe company's management's discussion and analysis for the nine monthperiod ended September 30, 2022 and annual information form datedOctober 8, 2022, which are available under the company's profileat www.sedar.com , and in filings made with the U.S. Securities and ExchangeCommission. Should one or more of these factors occur, or shouldassumptions underlying the forward-looking statements prove incorrect,actual results may vary materially from thosedescribed herein as intended, planned, anticipated, or expected. We donot intend and do not assume any obligation to update theseforward?looking statements, except as required by law. Any suchforward-looking statements represent management's estimates as of thedate of this press release. While we may elect to update suchforward-looking statements at some point in the future, we disclaimany obligation to do so, even if subsequent events cause our views tochange. Shareholders are cautioned not to put undue reliance on suchforward?looking statements.
Copyright (c) 2023 TheNewswire - All rights reserved.